
LADXD
Healthcare · Biotechnology
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 15, 2023 | After the close | — | -224.93 | — |
| Nov 17, 2022 | Time not confirmed | — | -277.70 | — |
| Aug 10, 2022 | Time not confirmed | — | -224.81 | — |
| May 11, 2022 | Time not confirmed | — | -385.02 | — |
| Nov 11, 2021 | Time not confirmed | — | -440.64 | — |
| Aug 24, 2021 | Time not confirmed | — | -321.70 | — |
| May 13, 2021 | Time not confirmed | — | -350.69 | — |
| Mar 26, 2021 | Time not confirmed | — | -387.00 | — |
| Nov 12, 2020 | Time not confirmed | — | -788.34 | — |
| Aug 10, 2020 | Time not confirmed | — | -400.35 | — |
| May 6, 2020 | Time not confirmed | — | -350.00 | — |
| Mar 5, 2020 | Time not confirmed | — | -889.09 | — |
| Nov 14, 2019 | Time not confirmed | — | -442.57 | — |
| Aug 9, 2019 | Time not confirmed | — | -383.31 | — |
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. In addition, the company's Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients…
| May 15, 2019 |
| Time not confirmed |
| — |
| -428.87 |
| — |
| Mar 29, 2019 | Time not confirmed | — | -694.88 | — |
| Nov 2, 2018 | Time not confirmed | — | -997.54 | — |
| Aug 6, 2018 | Time not confirmed | — | -993.79 | — |
| May 8, 2018 | Time not confirmed | — | -1487.90 | — |
| Mar 19, 2018 | Time not confirmed | — | -1600.00 | — |